Free On Demand: AST Documents Webinar
CLSI Documents for AST; What’s Available for You?
Online registration has closed, please contact Customer Service at +1.610.688.0100 to register.
Tuesday, May 22, 2018 | 1:00–2:00 PM Eastern (US) Time
At the conclusion of this program, the participant will be able to:
- Briefly describe the various format types (ie, paper, electronic) for CLSI documents and how they can be accessed.
- List all CLSI documents that focus on AST and reporting.
- Discuss how to make optimal use of CLSI documents M100 (tables for AST results), M45 (infrequently isolated or fastidious bacteria), M39 (antibiograms), M52 (verification of commercial identification and AST systems), M60 (tables for testing of yeasts), M27 (testing of yeasts) and M59 (epidemiological cutoff values).
- Explain how CLSI AST documents can be useful for individuals working with AST and/or reporting in clinical, public health, industrial, and academic settings.
April Bobenchik, PhD D(ABMM), Associate Director of Microbiology, Lifespan Academic Medical Center
Mariana Castanheira, PhD, Chief Operation Officer, JMI Laboratories
Cost: Free! Registration is required.
Members: FREENonmembers: FREE
Chairholder: April Bobenchik, PhD D(ABMM) and Mariana Castanheira, PhD
Date of Webinar: May 22, 2018
Free On Demand: AST Documents Webinar Additional Details
For nearly 5 decades, CLSI has been involved with publishing documents to guide antimicrobial susceptibility testing (AST) and reporting and/or monitoring of AST results. Any person involved with any aspect of AST is likely to be familiar with the CLSI AST “tables” (M100) that contain breakpoints and QC ranges for antibacterial agents. However, CLSI publishes nearly 20 other documents that relate to AST of human pathogens including bacteria, fungi, and some less commonly encountered microbes. The purpose of this webinar is to bring attendees up-to-date on CLSI AST documents and how recommendations provided in these documents can be used to address issues related to antimicrobial resistance in 2018.